Brian Windsor

Company: Aileron Therapeutics

Job title: President & Chief Executive Officer

Seminars:

Biomarker Strategies in the Clinical Development of LTI-03 in IPF 2:45 pm

Translational studies revealed key caveolin-1 regulated pro-fibrotic and lung epithelial cell mechanisms in IPF Caveolin scaffolding domain peptide LTI-03 modulates key biomarkers of aberrant fibroblast and epithelial cell activity in IPF LTI-03 modulates target-engagement biomarkers in a Phase 1b clinical trial in IPF patientsRead more

day: Day One Track A PM

OUR CONTACT DETAILS

Phone
UK: +44 (0)20 3141 8700
US: +1 617 455 4188

Email
info@hansonwade.com

JOIN OUR TEAM

We are always looking for ambitious people to join our team. You'll have opportunities to learn quickly, advance your career, and to meaningfully impact our customers and our business.

Click here to learn about careers.

ABOUT US

Hanson Wade specializes in scientific research across a comprehensive range of distinctive R&D areas. We deliver insight and connections to facilitate safe and effective drug development for more personalized and targeted patient populations.

EXPLORE OUR PRODUCTS

Conferences Beacon
Searchlight Intelligence

SEARCH

ORGANIZED BY

Terms & Conditions

Privacy Policy

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.